Is Viking Therapeutics Stock Really Going to $125?

Most veteran investors can attest that, although they're also often a complete bust, every now and then a biopharma stock dishes out a windfall gain.That's what the analyst community seems to expect from Viking Therapeutics (NASDAQ: VKTX) in the foreseeable future. The stock's current consensus price target of $92.94 is more than 200% above the ticker's present price, while one analyst -- BTIG's Justin Zelin -- says this stock's worth $125. That's more than 300% above its current value.The question is, what do so many stock-picking pros see in this extremely unprofitable pharmaceutical start-up?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool